Animal Models of Regression/progression of Kidney Disease

Overview

Journal Drug Discov Today Dis Models

Publisher Elsevier

Date 2015 Feb 28

PMID 25722733

Citations 18

Authors

Beom Jin Lim

Hai-Chun Yang

Agnes B Fogo

Affiliations

Soon will be listed here.

Abstract

Current medical therapies may delay chronic kidney disease progression. However, increasing experimental evidence indicates remission or even regression can be achieved. In order to study mechanisms progression vs. regression by different interventions, appropriate animal models and research design must be implemented. We review key information of selected models, including etiology, pathogenesis, procedure, time course and assessment of potential regression.

Citing Articles

Transcriptomic analysis of diabetic kidney disease and neuropathy in mouse models of type 1 and type 2 diabetes.

Elzinga S, Eid S, McGregor B, Jang D, Hinder L, Dauch J Dis Model Mech. 2023; 16(10).

PMID: 37791586 PMC: 10565109. DOI: 10.1242/dmm.050080.

Renoprotective Impacts of Ethanol-Ethyl Acetate Extract on Combined Streptozotocin and Unilateral Nephrectomy-Induced Diabetic Nephropathy in Mice.

Chiang K, Chiu Y, Yar N, Chen Y, Cheng C, Liu Y Int J Mol Sci. 2023; 24(5).

PMID: 36901874 PMC: 10002342. DOI: 10.3390/ijms24054443.

Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.

Badal S, Al Tuhaifi T, Yu Y, Lopez D, Plato C, Joly K Kidney360. 2022; 3(7):1169-1182.

PMID: 35919527 PMC: 9337896. DOI: 10.34067/KID.0001032022.

Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes.

Jeruschke S, Alex D, Hoyer P, Weber S Sci Rep. 2022; 12(1):12297.

PMID: 35853959 PMC: 9296604. DOI: 10.1038/s41598-022-16333-w.

CPT1α maintains phenotype of tubules via mitochondrial respiration during kidney injury and repair.

Yuan Q, Lv Y, Ding H, Ke Q, Shi C, Luo J Cell Death Dis. 2021; 12(8):792.

PMID: 34392303 PMC: 8364553. DOI: 10.1038/s41419-021-04085-w.

References

Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H . "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension. 2008; 53(1):83-9. DOI: 10.1161/HYPERTENSIONAHA.108.122721. View

Wilmer W, Hebert L, Lewis E, Rohde R, Whittier F, Cattran D . Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis. 1999; 34(2):308-14. DOI: 10.1016/s0272-6386(99)70360-4. View

Galichon P, Vittoz N, Xu-Dubois Y, Cornaire E, Vandermeersch S, Mesnard L . Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation. 2011; 92(9):993-8. DOI: 10.1097/TP.0b013e31822fa495. View

Singh A, Junemann A, Muthuraman A, Jaggi A, Singh N, Grover K . Animal models of acute renal failure. Pharmacol Rep. 2012; 64(1):31-44. DOI: 10.1016/s1734-1140(12)70728-4. View

Fassi A, Sangalli F, Maffi R, Colombi F, Mohamed E, Brenner B . Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit. J Am Soc Nephrol. 1998; 9(8):1399-406. DOI: 10.1681/ASN.V981399. View

Ma L, Nakamura S, Aldigier J, Rossini M, Yang H, Liang X . Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005; 16(4):966-76. DOI: 10.1681/ASN.2004060492. View

Brosius 3rd F, Alpers C, Bottinger E, Breyer M, Coffman T, Gurley S . Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009; 20(12):2503-12. PMC: 4075053. DOI: 10.1681/ASN.2009070721. View

Elzinga L, Rosen S, Bennett W . Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol. 1993; 4(2):214-21. DOI: 10.1681/ASN.V42214. View

Ofstad J, Iversen B . Glomerular and tubular damage in normotensive and hypertensive rats. Am J Physiol Renal Physiol. 2004; 288(4):F665-72. DOI: 10.1152/ajprenal.00226.2004. View

10.

Adamczak M, Gross M, Krtil J, Koch A, Tyralla K, Amann K . Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol. 2003; 14(11):2833-42. DOI: 10.1097/01.asn.0000095248.91994.d3. View

11.

Piecha G, Koleganova N, Gross M, Geldyyev A, Adamczak M, Ritz E . Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol. 2008; 295(1):F137-44. DOI: 10.1152/ajprenal.00065.2008. View

12.

Teles F, Machado F, Ventura B, Malheiros D, Fujihara C, Silva L . Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int. 2008; 75(1):72-9. DOI: 10.1038/ki.2008.528. View

13.

Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A . Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010; 299(5):F1203-11. DOI: 10.1152/ajprenal.00045.2010. View

14.

Goldstein R, Tarloff J, Hook J . Age-related nephropathy in laboratory rats. FASEB J. 1988; 2(7):2241-51. DOI: 10.1096/fasebj.2.7.3280378. View

15.

Tesch G, Allen T . Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton). 2007; 12(3):261-6. DOI: 10.1111/j.1440-1797.2007.00796.x. View

16.

Yang H, Zuo Y, Fogo A . Models of chronic kidney disease. Drug Discov Today Dis Models. 2011; 7(1-2):13-19. PMC: 3030258. DOI: 10.1016/j.ddmod.2010.08.002. View

17.

Ruggenenti P, Brenner B, Remuzzi G . Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron. 2001; 88(3):254-9. DOI: 10.1159/000045998. View

18.

Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M . Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol. 2011; 179(2):628-38. PMC: 3157222. DOI: 10.1016/j.ajpath.2011.04.003. View

19.

Yang H, Ma L, Ma J, Fogo A . Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 2006; 69(10):1756-64. DOI: 10.1038/sj.ki.5000336. View

20.

Boffa J, Lu Y, Placier S, Stefanski A, Dussaule J, Chatziantoniou C . Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003; 14(5):1132-44. DOI: 10.1097/01.asn.0000060574.38107.3b. View